SB 6116
In CommitteeSenate
Vapor products/tax
Restoring funding for cancer research and public health services.
This status may be delayed. See Action History below for the latest updates.
How does a bill become law?
- Introduced: The bill is filed and assigned a number.
- Committee: A subject-matter committee holds hearings, takes public testimony, and decides whether to advance the bill.
- Floor Vote: The full chamber (House or Senate) debates and votes on the bill.
- Opposite Chamber: The bill repeats the committee and floor vote process in the other chamber.
- Governor: The Governor reviews the bill and decides whether to sign or veto it.
- Signed: The bill has been signed into law.
AI Analysis
This bill expands Washington’s definition of 'tobacco products' to include vapor and nicotine-containing products (e.g., e-cigarettes), making them subject to existing tobacco tax laws. It also updates tax calculation rules for affiliated businesses and declares the change urgent to preserve public health funding. The bill takes effect immediately and applies retroactively to January 1, 2026.
- Amends the definition of 'tobacco products' to explicitly include any product containing nicotine—whether derived from tobacco or synthetically produced—that is intended for human consumption via oral, nasal, or other absorption routes, including vapor products (e.g., e-cigarettes).
- Clarifies that cigarettes, vapor products approved by the U.S. FDA as of December 31, 2024, and certain FDA-approved drug-device combinations are excluded from the new tax definition.
- Updates the definition of 'taxable sales price' to address pricing and tax calculations for sales between affiliated companies (e.g., manufacturer to affiliated distributor), ensuring fair market-value-based taxation.
- Includes vapor product sellers and manufacturers in the scope of 'distributors' and 'retailers' under the tax law, requiring them to comply with licensing, reporting, and tax collection rules.
- Declares the bill an emergency measure, effective immediately upon passage, and applies retroactively to January 1, 2026.
Who is affected
- Vapor product retailers and distributors — Businesses that sell or distribute vapor products (e.g., e-cigarettes, vapes) in Washington may face new tax reporting and compliance requirements under updated definitions and tax rules for tobacco products that now include nicotine-containing vapor products.
- Vapor product manufacturers — Manufacturers and brands that produce vapor or nicotine-containing products may need to adjust pricing, contracts, and tax calculations—especially if they sell through affiliated entities.
- State and local governments — State and local governments may benefit from increased tax revenue from vapor products, which will support cancer research and public health programs.
- Vapor product consumers — Consumers who use vapor products may see higher prices if retailers pass on increased tax costs, though the bill itself does not directly set consumer prices.
Pro/Con Analysis
Stronger case for benefits
Potential Benefits (5)
Bringing synthetic-nicotine vapor products under the tobacco tax framework aligns tax policy with public health goals — recognizing that nicotine delivery, regardless of source, poses similar health risks and youth appeal, and enabling uniform enforcement and age restrictions.
Public SafetyRef: Sec. 1(21)By closing the synthetic-nicotine loophole, the bill helps prevent manufacturers from circumventing tobacco control policies through product reformulation, strengthening the state’s ability to curb youth vaping and protect long-term public health.
Public SafetyRef: Sec. 1(21)The retroactive effective date (January 1, 2026) ensures revenue stability and fairness by preventing businesses from gaining competitive advantage through tax-avoidant product design during the 2026 fiscal year.
Public SafetyRef: Sec. 1(21)The bill’s exclusion of FDA-approved drug-device combinations supports evidence-based cessation, avoiding unintended disincentives to medically supervised nicotine replacement therapy.
Public SafetyRef: Sec. 1(21)The definition update harmonizes Washington’s tax code with federal tobacco control frameworks (e.g., FDA authority), reducing regulatory fragmentation and supporting coordinated multi-jurisdictional public health responses.
Public SafetyRef: Sec. 1(21)
Potential Concerns (5)
Expanding the definition of 'tobacco products' to include synthetic nicotine vapor products may improve public health outcomes by enabling consistent regulation and taxation of all nicotine-delivery products, reducing youth access and supporting enforcement consistency across product types.
Public SafetyRef: Sec. 1(21)The explicit inclusion of synthetic nicotine products closes a regulatory loophole that previously allowed manufacturers to avoid tobacco taxes by reformulating products with non-tobacco-derived nicotine — a practice that undermined public health policy and revenue collection.
Public SafetyRef: Sec. 1(21)Excluding FDA-approved drug-device combinations (e.g., FDA-authorized nicotine replacement therapies) from the tax definition preserves access to smoking-cessation tools, supporting public health goals without penalizing cessation efforts.
Public SafetyRef: Sec. 1(21)The retroactive application to January 1, 2026, creates administrative complexity for businesses that may have operated under the prior interpretation (excluding synthetic nicotine from tobacco tax), potentially leading to compliance errors or disputes during the audit period.
Public SafetyRef: Sec. 1(21)While the bill excludes FDA-approved vapor products as of December 31, 2024, it does not exclude future FDA-authorized products — meaning evolving medical evidence could be outpaced by statutory language, risking misclassification of emerging cessation technologies.
Public SafetyRef: Sec. 1(21)
Who Is Most Affected
Vapor product retailers and distributors will face new licensing, reporting, and tax collection obligations under the expanded definition, increasing administrative burden and compliance costs — especially for small shops that lack dedicated tax departments.
Manufacturers of synthetic-nicotine vapor products may need to restructure pricing, contracts, and intercompany transfers to comply with the new affiliated-sales tax rules, potentially reducing profit margins or requiring price adjustments.
State and local governments gain new revenue from taxing previously untaxed synthetic-nicotine products, supporting cancer research and public health programs — though this benefit is offset for some tribes operating on sovereign land.
Consumers may face higher prices as retailers pass on tax costs, disproportionately affecting low-income users who rely on vapor products as less-harm alternatives to smoking — though the public health benefits (e.g., reduced youth access) may offset long-term health costs.